<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518137</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-008-AST-001</org_study_id>
    <nct_id>NCT04518137</nct_id>
  </id_info>
  <brief_title>A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)</brief_title>
  <official_title>An Open-Label, Single-Arm Basket Study of ATG-008 for the Treatment of Patients With Advanced Solid Tumors Harboring NFE2L2, STK11, RICTOR or Other Specific Genetic Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Antengene Corporation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antengene Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm and open-label study of ATG-008 for the Treatment of Patients With&#xD;
      advanced Solid Tumors harboring NFE 2L2, STK11, RICTOR or other specific genetic alterationts&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm and open-label study. Approximately 10-12 patients will be enrolled per&#xD;
      each genetic alterration group in the study. ATG-008 is the monotherapy for advanced solid&#xD;
      tumors with 30mg QD. The clinical efficacy, safety and tolerability of ATG-008 will be&#xD;
      evaluated. Addtionalal dose levels may apply after the efficacy/safety and tolerabitly of&#xD;
      30mg QD has been accessed by Sponosor and study steering committee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>19 months</time_frame>
    <description>Percentage of subjects with PR, or CR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>19 months</time_frame>
    <description>Duration of time from first occurrence of CR or PR until the first date that disease progression is objectively documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>19 months</time_frame>
    <description>Proportion of patients who achieve CR, PR, or SD for a minimum of 4 weeks, following the first dose of study drug (i.e., CR+PR+SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>19 months</time_frame>
    <description>Duration of time from the first dose of study drug until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>19 months</time_frame>
    <description>Duration of time from the first dose of study drug until progression or death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ATG-008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will be treated with ATG-008 at an oral fixed milligram (mg) dose of 30 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle</intervention_name>
    <description>48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle</description>
    <arm_group_label>ATG-008</arm_group_label>
    <other_name>ATG-008</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females of 18 years of age or older&#xD;
&#xD;
          2. Have histologically-proven measurable, or evaluable advanced (systemically or locally&#xD;
             progressive), or metastatic solid tumors or the locally advanced disease is not&#xD;
             amenable to local therapy, who have failed, or are intolerant to standard therapy or&#xD;
             for whom no standard therapy is available. (For patients with hepatocellular&#xD;
             carcinoma, the diagnosis needs to be supported by dynamic computed tomography&#xD;
             [CT]/magnetic resonance imaging, if pathological confirmation is not attainable) and&#xD;
             agree to provide fresh tumor tissues for genomic analysis.&#xD;
&#xD;
          3. Harboring with below specific genetic alterations:&#xD;
&#xD;
               1. NFE2L2 mutations&#xD;
&#xD;
               2. STK11 mututions&#xD;
&#xD;
               3. RICTOR amplifications&#xD;
&#xD;
               4. Other genetic alterations maybe enrolled after discussion with Sponsor medical&#xD;
                  monitor&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of &lt; 2 at the screening.&#xD;
&#xD;
          5. Able to comprehend and provide informed consent.&#xD;
&#xD;
          6. A life expectancy longer than 3 months in the opinion of the Investigator.&#xD;
&#xD;
          7. Adequate hematologic functions, as defined by: absolute neutrophil counts ≥ 1500/mm3;&#xD;
             a hemoglobin level ≥ 9 g/dL; a platelet count ≥ 100,000/mm3.&#xD;
&#xD;
          8. Adequate hepatic function defined by: a total bilirubin level ≤ 1.5 × of upper limit&#xD;
             of normal (ULN); aspartate transaminase and alanine transaminase levels ≤ 2.5 ×&#xD;
             ULN(AST and ALT ≤5 × ULN for subjects with liver metastasis).&#xD;
&#xD;
          9. Adequate renal function, as defined by the creatinine clearance ≥ 50 mL/minute (as&#xD;
             calculated by the Cockcroft-Gault formula).&#xD;
&#xD;
         10. Females of child-bearing potential must have a negative pregnancy test upon entry into&#xD;
             this study and must be willing to use highly effective birth control upon enrollment,&#xD;
             during the Treatment Phase and for 180 days following the last dose of study drug. A&#xD;
             female is considered of child-bearing potential following menarche and until becoming&#xD;
             postmenopausal (no menstrual period for a minimum of 12 months) unless permanently&#xD;
             sterile (undergone a hysterectomy, bilateral salpingectomy, or bilateral&#xD;
             oophorectomy).&#xD;
&#xD;
         11. If male, must be surgically sterile or willing to use highly effective birth control&#xD;
             upon enrollment, during the Treatment Phase, and for 180 days following the last dose&#xD;
             of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Persistent ≥ Grade 2 toxicities from prior therapies, with the exception of alopecia&#xD;
             of any grade, Grade ≤ 2 peripheral neuropathy, and laboratory values listed per the&#xD;
             inclusion criteria.&#xD;
&#xD;
          2. Concurrent unstable or uncontrolled medical conditions, including:&#xD;
&#xD;
               1. Active systemic infections;&#xD;
&#xD;
               2. Poorly controlled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic&#xD;
                  blood pressure ≥ 100 mmHg), or poor compliance with antihypertensive agents;&#xD;
&#xD;
               3. Clinically significant arrhythmia, unstable angina pectoris, congestive heart&#xD;
                  failure (Class II or IV of New York Heart Association) or acute myocardial&#xD;
                  infarction;&#xD;
&#xD;
               4. Uncontrolled diabetes or poor compliance with hypoglycemic agents (as defined:&#xD;
                  HbA1c &gt;7%);&#xD;
&#xD;
               5. The presence of chronically unhealed wound or ulcers;&#xD;
&#xD;
               6. Other chronic diseases, which, in the opinion of the Investigator, could&#xD;
                  compromise safety of the patient or the integrity of the study.&#xD;
&#xD;
          3. Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the&#xD;
             cervix. (Patients with a previous malignancy but without evidence of disease for ≥ 5&#xD;
             years are allowed to participate).&#xD;
&#xD;
          4. Females who are pregnant, lactating, or intend to become pregnant during their&#xD;
             participation in this study.&#xD;
&#xD;
          5. Known history of human immunodeficiency virus infection.&#xD;
&#xD;
          6. Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose. The following are exceptions to this criterion:&#xD;
&#xD;
               1. Intranasal, inhaled, topical steroids or local steroid injections (eg,&#xD;
                  intra-articular injection), OR&#xD;
&#xD;
               2. systemic corticosteroids at physiologic doses not to exceed 10 mg/day of&#xD;
                  prednisone or equivalent, OR&#xD;
&#xD;
               3. steroids as premedication for hypersensitivity reactions (eg, CT scan&#xD;
                  premedication).&#xD;
&#xD;
          7. History of primary immunodeficiency or allogeneic transplantation.&#xD;
&#xD;
          8. Active hepatitis B (HBsAg active),Active hepatitis C virus (HCV) infection, defined as&#xD;
             having a positive HCV antibody test followed by a positive HCV RNA test at Screening.&#xD;
&#xD;
          9. The patient is the Investigator, sub-investigator or anyone directly involved in the&#xD;
             conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academay of Medical Science and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jasmine Sun, MD</last_name>
    <phone>13701803117</phone>
    <email>jasmine.sun@antengene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lanping Shi, MD</last_name>
    <phone>15216683690</phone>
    <email>lanping.shi@antengene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chongqing university cancer hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>qi zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of xiamen university</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>feng ye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xingchen Peng</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

